基于 1 个已确定 T+90 收益的买入信号。收益基准:公布次日的收盘价。
无可用的信号评分。
Discover the full record of transactions filed by Philippe Roussouly, 董事长兼首席执行官. Insider active across 1 company, notably S.M.A.I.O. Cumulatively, 1 disclosures have been logged. Split: 1 buy · 0 sell. Total volume traded: €44k. History available since 16 March 2023. The latest transaction was filed on 16 March 2023 (Acquisition). Regulator: AMF. All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 条申报中的 1 条
Philippe Roussouly is the founder and Chief Executive Officer of SMAIO, a French medtech company focused on complex spine surgery and spinal realignment solutions. Founded in 2009, SMAIO was built around a model that combines clinical expertise, medical data, imaging, and implantable devices to improve outcomes in spinal deformity and complex orthopaedic procedures. As the company’s top executive, he oversees SMAIO’s strategy, product development, international expansion, and investor relations. Company investor materials show that in 2024 he led a major strategic shift by establishing SMAIO’s general and commercial management in the United States, a critical market for spinal implants, with the goal of accelerating growth and strengthening the group’s presence in North America. His career is closely tied to the orthopaedics and spine-surgery ecosystem. Sector and financial sources describe him as the company’s key leader, responsible for strategic direction, market development, and the relationship with institutional investors and industrial partners. He also played a central role in SMAIO’s listing on Euronext Growth Paris, a milestone that improved the company’s access to capital and visibility in the public markets. Under his leadership, SMAIO has strengthened both its scientific credibility and commercial reach. The company has highlighted the expansion of its training programs, deeper collaboration with reference medical centers, and the creation of a North American Scientific Advisory Board. It also emphasizes its capabilities in data, artificial intelligence, and spinal alignment planning, reflecting a clear focus on personalized surgery and precision medicine. Overall, Philippe Roussouly represents an entrepreneur-operating executive profile: he combines medical-sector expertise, company-building, stock-market discipline, and international execution. His leadership has helped transform SMAIO from a clinically driven innovator into a listed medtech company with a growing footprint in North America.